The number of active drug shortages in the United States declined by 23% in 2024 compared to the previous year, according to the annual Medicine Supply Chain Resilience Report published by U.S. Pharmacopeia (USP). While this marks the second consecutive year of improvement, the average duration of a shortage has reached 5.3 years, indicating that while new shortages are emerging less frequently, systemic issues keep existing medications off pharmacy shelves for longer periods.
Why are drug shortages lasting longer?
The primary driver of prolonged shortages is the fragility of the global pharmaceutical supply chain. According to Food and Drug Administration (FDA) analysis, most drug shortages occur due to manufacturing and quality problems, rather than a lack of raw materials. When a facility experiences a production disruption—such as a failure to meet Current Good Manufacturing Practice (CGMP) standards—the time required to remediate the facility or transfer production to an alternative site often takes years. The USP data confirms that 39% of medicines currently in short supply have been unavailable for more than five years, a trend that suggests manufacturers struggle to restore capacity once a line is compromised.
Which drugs are most affected?
Shortages currently span 130 distinct therapeutic categories, affecting a wide range of patient populations. According to the American Society of Health-System Pharmacists (ASHP), these include critical medications such as sterile injectables, oncology drugs, and antibiotics. Unlike retail medications, which can sometimes be substituted with different strengths or brands, many of these injectable drugs lack therapeutic alternatives, forcing hospitals to ration supplies or delay procedures. The diversity of affected categories highlights that the problem is not isolated to a single class of medicine but is instead a systemic issue across the entire pharmaceutical manufacturing sector.
Comparison of shortage trends
The current landscape shows a shift in how shortages manifest compared to historical data.
| Metric | 2019 Data | 2024 Data |
| :— | :— | :— |
| Average Shortage Duration | 2 years | 5.3 years |
| Shortage Frequency | Higher volatility | 23% decline in new cases |
The data reveals a “bottleneck” effect. While the industry is becoming slightly more efficient at preventing new shortages from starting, the “legacy” shortages—drugs that have been unavailable for years—remain trapped in the system. This creates a scenario where the total count of shortages drops, but the clinical impact on patient care remains severe because the drugs that stay in short supply are often those with no viable alternatives.
What happens next for patients and providers?
The FDA continues to utilize its authority under the Food and Drug Administration Safety and Innovation Act (FDASIA) to require manufacturers to notify the agency of potential supply disruptions. However, experts note that notification is only the first step. Future mitigation strategies focus on diversifying manufacturing locations and increasing domestic production of “essential medicines.” For patients, the current environment necessitates proactive communication with pharmacists. If a specific medication is unavailable, providers are encouraged to consult the FDA Drug Shortages Database to identify if a therapeutic equivalent or alternative dosage form is currently available to ensure continuity of care.